At a glance
ClinicalIndex Comparison RecordPhase 1Recruiting· 240 target
Drug / intervention
ILB-3101biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT06426680Phase 1RecruitingUpdate OverdueUpdated 18mo ago · Completion was 6mo agoEnrollment Stalled
Update Overdue
Phase I/II Study of the ILB-3101 in Patients with Advanced Solid Tumors
In Brief
A Phase 1 clinical trial evaluating ILB-3101 for Advanced Solid Tumor. Currently recruiting, targeting 240 participants across 1 site.
Signals
Enrollment appears stalled
Detailed Summary
ILB-3101 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. The objectives of this study are to investigate the safety, tolerability, pharmacokinetics and anti-tumor activity of ILB-3101 in Chinese advanced solid tumor patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumor
CountriesChina
Collaborators--
Timeline
Phase 1RecruitingOverdue
20252026
First PostedMay 2024
Enrollment StartOct 2024
Primary CompletionDec 2025
Study CompletionMar 2026
TodayJul 2026
First PostedMay 23, 2024
Enrollment StartOct 30, 2024
Primary CompletionDec 1, 2025
Study CompletionMar 1, 2026
TodayJul 1, 2026
Enrollment to primary: 1.1 yearsPosted 2.1 years ago
Interventions
ILB-3101biological
There are eight escalating dose cohorts.